drugset / Trial / NCT04116658
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
Timeline
- Start
- 2020-07-13
- Primary completion
- 2024-03-04
- Completion
- 2024-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | EO2401 | Vaccine | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |